Skip to content

Study · Animal study (in vivo) · mouse · 2015

7 results

Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.

Shailubhai K, Palejwala V, Arjunan KP, Saykhedkar S, Nefsky B, Foss JA, Comiskey S, Jacob GS, Plevy SE

World journal of gastrointestinal pharmacology and therapeutics1 Nov 2015Cited by 59 (Europe PMC)

PMID26558155 (opens in a new tab)PMCIDPMC4635161 (opens in a new tab)DOI10.4292/wjgpt.v6.i4.213 (opens in a new tab)PepBankPUB-26558155
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with DSS- or TNBS-induced colitis, plecanatide ameliorated colitis as assessed by body weight.

    In plain wordsIn mice with chemically induced colitis, plecanatide improved the body weight assessment.

    Peptide
    Plecanatide
    Outcome
    Direction not reportedBody weight
    Study

    mousen: not reported in source

    DSS- and TNBS-induced acute colitis
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.05-0.5 mg/kg once daily · oralAs given in this study (mouse).

    Source sentences

    Summary
    Once-daily treatment by oral gavage with either of these analogs (0.05-0.5 mg/kg) ameliorated colitis in both DSS and TNBS-induced models of acute colitis, as assessed by body weight, reduction in colitis severity (P < 0.05) and disease activity index (P < 0.05).
    1 context sentence
    Summary · context
    Effect of oral treatment with test agents on amelioration of acute colitis induced either by dextran sulfate sodium (DSS) in drinking water or by rectal instillation of trinitrobenzene sulfonic (TNBS) acid, was examined in BALB/c and/or BDF1 mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with DSS- or TNBS-induced colitis, plecanatide reduced colitis severity (P < 0.05).

    In plain wordsIn mice with chemically induced colitis, plecanatide reduced colitis severity.

    Peptide
    Plecanatide
    Outcome
    DecreaseColitis severity
    Study

    mousen: not reported in source

    DSS- and TNBS-induced acute colitis
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.05-0.5 mg/kg once daily · oralAs given in this study (mouse).

    Source sentences

    Summary
    Once-daily treatment by oral gavage with either of these analogs (0.05-0.5 mg/kg) ameliorated colitis in both DSS and TNBS-induced models of acute colitis, as assessed by body weight, reduction in colitis severity (P < 0.05) and disease activity index (P < 0.05).
    1 context sentence
    Summary · context
    Effect of oral treatment with test agents on amelioration of acute colitis induced either by dextran sulfate sodium (DSS) in drinking water or by rectal instillation of trinitrobenzene sulfonic (TNBS) acid, was examined in BALB/c and/or BDF1 mice.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with DSS- or TNBS-induced colitis, plecanatide reduced disease activity index (P < 0.05).

    In plain wordsIn mice with chemically induced colitis, plecanatide reduced disease activity.

    Peptide
    Plecanatide
    Outcome
    DecreaseDisease activity index
    Study

    mousen: not reported in source

    DSS- and TNBS-induced acute colitis
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.05-0.5 mg/kg once daily · oralAs given in this study (mouse).

    Source sentences

    Summary
    Once-daily treatment by oral gavage with either of these analogs (0.05-0.5 mg/kg) ameliorated colitis in both DSS and TNBS-induced models of acute colitis, as assessed by body weight, reduction in colitis severity (P < 0.05) and disease activity index (P < 0.05).
    1 context sentence
    Summary · context
    Effect of oral treatment with test agents on amelioration of acute colitis induced either by dextran sulfate sodium (DSS) in drinking water or by rectal instillation of trinitrobenzene sulfonic (TNBS) acid, was examined in BALB/c and/or BDF1 mice.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with colitis, plecanatide amelioration was comparable to oral sulfasalazine.

    In plain wordsIn mice with colitis, plecanatide produced improvement comparable to sulfasalazine.

    Peptide
    Plecanatide
    Outcome
    No significant changeColitis amelioration
    Study

    mousen: not reported in source

    Comparator
    Sulfasalazine
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.05-0.5 mg/kg once daily · oralAs given in this study (mouse).

    Source sentences

    Summary
    Amelioration of colitis by either of the drug candidates was comparable to that achieved by orally administered sulfasalazine or 5-ASA.
    1 context sentence
    Summary · context
    Once-daily treatment by oral gavage with either of these analogs (0.05-0.5 mg/kg) ameliorated colitis in both DSS and TNBS-induced models of acute colitis, as assessed by body weight, reduction in colitis severity (P < 0.05) and disease activity index (P < 0.05).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with colitis, plecanatide amelioration was comparable to oral 5-ASA.

    In plain wordsIn mice with colitis, plecanatide produced improvement comparable to 5-ASA.

    Peptide
    Plecanatide
    Outcome
    No significant changeColitis amelioration
    Study

    mousen: not reported in source

    Comparator
    5-ASA
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.05-0.5 mg/kg once daily · oralAs given in this study (mouse).

    Source sentences

    Summary
    Amelioration of colitis by either of the drug candidates was comparable to that achieved by orally administered sulfasalazine or 5-ASA.
    1 context sentence
    Summary · context
    Once-daily treatment by oral gavage with either of these analogs (0.05-0.5 mg/kg) ameliorated colitis in both DSS and TNBS-induced models of acute colitis, as assessed by body weight, reduction in colitis severity (P < 0.05) and disease activity index (P < 0.05).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In TCRα knockout mice, plecanatide ameliorated spontaneous colitis.

    In plain wordsIn mice lacking TCRα, plecanatide improved spontaneous colitis.

    Peptide
    Plecanatide
    Outcome
    DecreaseSpontaneous colitis
    Study

    mousen: not reported in source

    TCRα knockout spontaneous colitis
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (mouse).

    Source sentences

    Summary
    Plecanatide also effectively ameliorated colitis in TCRα(-/-) mice, a model of spontaneous colitis.
    1 context sentence
    Summary · context
    Additionally, the effect of orally administered plecanatide on the spontaneous colitis in T-cell receptor alpha knockout (TCRα(-/-)) mice was also examined.
  7. 07LabIn vitro (cells)Activity measurement

    In T84 cells, plecanatide exhibited potent cGMP-stimulatory activity.

    In plain wordsIn cells, plecanatide stimulated cGMP production.

    Peptide
    Plecanatide
    Outcome
    IncreasecGMP stimulation
    Study

    humann: not reported in source

    T84 colon carcinoma cells
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    As expected from the agonists of GC-C, both plecanatide and dolcanatide exhibited potent cGMP-stimulatory activity in T84 cells.
    1 context sentence
    Summary · context
    The cyclic guanosine monophosphate (cGMP) stimulatory potency of plecanatide and dolcanatide was measured using a human colon carcinoma T84 cell-based assay.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.